Zhejiang Anglikang Pharmaceutical Hits Day Low Amid Price Pressure at CNY 29.44

Zhejiang Anglikang Pharmaceutical Co. experienced a notable decline today, with the stock dropping by 5.7% on June 8, 2026. The stock reached an intraday low of CNY 29.44, reflecting a challenging trading session. Over the past week, the stock has seen a more significant decrease of 12.89%, contrasting with the China Shanghai Composite's decline of 2.43% during the same period. In terms of longer-term performance, Zhejiang Anglikang has generated a substantial return of 52.6% over the past year, significantly outperforming the China Shanghai Composite, which reported a gain of 16.95%. However, year-to-date performance shows a decline of 10.68%, while the broader index has remained relatively stable with a decrease of just 0.24%. Financial metrics indicate a mixed picture for the company. Despite a strong net profit growth of 172.44% in the last nine months, the stock's valuation remains high, with a price-to-book ratio of 3.37 and a return on equity of 9.35%. The company operates within the pharmaceuticals and biotechnology sector, holding a mid-cap market capitalization of CNY 5,547 million.